Duopharma Biotech Bhd 2024 SR
The report details Duopharma Biotech's sustainability progress for 2024, highlighting its 10th standalone edition. Key achievements include a 0.6% reduction in Scopes 1 and 2 emissions, the establishment of a Scope 3 baseline for six categories, and becoming the first Malaysian company to sign the UNGC Forward Faster for Water Resilience. The company also achieved EU GMP certification for its HAPI plant and launched several new generic medications for cancer, heart, and kidney patients. Socially, it introduced a Labour Rights Policy and maintained 36% women representation on its Board.
Company: Duopharma Biotech Bhd
Sector: Health Care
Country: Malaysia
Year: 2024
Type: SR
Pages: 164
Duopharma Biotech Bhd
Sustainability Report
The report details Duopharma Biotech's sustainability progress for 2024, highlighting its 10th standalone edition. Key achievements include a 0.6% reduction in Scopes 1 and 2 emissions, the establishment of a Scope 3 baseline for six categories, and becoming the first Malaysian company to sign the UNGC Forward Faster for Water Resilience. The company also achieved EU GMP certification for its HAPI plant and launched several new generic medications for cancer, heart, and kidney patients. Socially, it introduced a Labour Rights Policy and maintained 36% women representation on its Board.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 7, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees